Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Claud B who wrote (2817)	3/18/1998 8:24:00 PM
From: Bill Wexler	Respond to of 7041

Many times it is. It is difficult to tell without tracing through all the clearing records. Sometimes its obvious (an example I gave was how Wesels Arnold took a large position in AVNT stock prior to the TMAI merger to obtain a better conversion rate. Wesels Arnold received a fee for handling the merger and also made a market in AVNT stock).

To: Claud B who wrote (2817)	3/19/1998 9:14:00 AM
From: Dauntless	Read Replies (1) \| Respond to of 7041

Claude - holy jumping beans Press release from Zonagen today - Mexican filing ===================================================================== Thursday March 19, 8:32 am Eastern Time Company Press Release Zonagen Announces Product Registration Filed in Mexico for Vasomax THE WOODLANDS, Texas--(BW HealthWire)--March 19, 1998-- Zonagen, Inc. (Nasdaq: ZONA; Pacific: ZNG) today announced that Schering-Plough Corporation (NYSE: SGP - news) has filed a Product Registration Application in Mexico for Vasomax(TM) for the treatment of Male Erectile Dysfunction (MED). ''The Product Registration Application in Mexico for Vasomax(TM) is an important step in the process of commercialization,'' said Joseph Podolski, president and chief operating officer of Zonagen. Vasomax(TM), Zonagen's immediate-release oral formulation of phentolamine mesylate, was licensed worldwide to Schering-Plough in November 1997 for the treatment of MED. Vasomax has been tested in over 300 men in Mexico and more than 3,000 men in the U.S. Zonagen, Inc. specializes in the development of products and services for the management of reproductive health. Its technologies focus on the areas of urology, female health and contraception. Through its wholly owned subsidiary, Fertility Technologies, Inc. (FTI), Zonagen sells devices, instruments and supplies to the fertility specialist and the OB/GYN. This release may contain certain forward-looking statements, including statements regarding the clinical investigation, timing, approval and commercialization of products that involve a number of risks and uncertainties. Actual events or results may differ from the company's expectations as a result of risk factors identified in the Company's reports and registrations as filed with the U.S. Securities Exchange Commission. ===================================================================== Amazing how Zonagen & SGP continue to waste time and money by pursuing the commercialization of this old, worthless compound. There must not be a SINGLE PERSON in either organization that can accurately assess the potential of their own drugs. Perhaps they could hire Asensio or Wexler as a consultant & avoid such amateurish mistakes in the future.